Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886

被引:34
作者
Kusunoki, M [1 ]
Tsutsumi, K
Hara, T
Ogawa, H
Nakamura, T
Miyata, T
Sakakibara, F
Fukuzawa, Y
Suga, T
Kakumu, S
Nakaya, Y
机构
[1] Aichi Med Univ, Dept Internal Med 1, Aichi 48011, Japan
[2] Aichi Med Univ, Inst Phys, Aichi 48011, Japan
[3] Otsuka Pharmaceut Factory Inc, Tokushima, Japan
[4] Yamagata Univ, Fac Engn, Yamagata, Japan
[5] Univ Tokyo, Sch Med, Tokyo, Japan
[6] Univ Tokushima, Sch Med, Tokushima, Japan
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2002年 / 51卷 / 06期
关键词
D O I
10.1053/meta.2002.32732
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin resistance results in accumulation of triglyceride content and reduction of glycogen content in skeletal muscle. However, very few studies have measured lipid content and glycogen content in liver associated with insulin resistance. We studied the relationship between liver lipid content, liver glycogen, and insulin resistance in high-fat-fed rats, which are animal models of insulin resistance. High-fat-fed rats were hyperlipidemic, hyperglycemic, and hyperinsulinemic. Furthermore, the glucose infusion rates (GIR) were lower (normal rats, 10.35 +/- 1.66; high-fat-fed rats, 4.86 +/- 0.93 mg/kg/min; P <.01) and the triglyceride and cholesterol contents in liver were higher in the high-fat-fed rats than in normal rats. On the other hand, the glycogen content in liver was lower than in normal rats. There was an inverse relationship between liver triglyceride content and liver glycogen content. When the lipoprotein lipase (LPL) activator NO-1886 was administered to the high-fat-fed rats at a daily dose of 50 mg/kg body weight for 10 weeks, GIR (9.87 +/- 3.76 mg/kg/min, P <.05 v high-fat-fed control group) improved, causing an improvement of the hyperlipidemia, hyperglycemia, and hyperinsulinemia. Furthermore, NO-1886 decreased triglyceride and cholesterol concentrations and increased glycogen content in liver of the high-fat-fed rats. In this study, we found that insulin resistance caused fatty liver and reduced glycogen content in liver. Administration of the LPL activator NO-1886 improved the insulin resistance, resulting in an improvement in the relationship between triglyceride and glycogen content in liver of high-fat-fed rats. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:792 / 795
页数:4
相关论文
共 13 条
[11]   CORRECTION OF HYPERTRIGLYCERIDEMIA WITH LOW HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL BY THE NOVEL COMPOUND NO-1886, A LIPOPROTEIN LIPASE-PROMOTING AGENT, IN STZ-INDUCED DIABETIC RATS [J].
TSUTSUMI, K ;
INOUE, Y ;
SHIMA, A ;
MURASE, T .
DIABETES, 1995, 44 (04) :414-417
[12]   THE NOVEL COMPOUND NO-1886 INCREASES LIPOPROTEIN-LIPASE ACTIVITY WITH RESULTING ELEVATION OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL, AND LONG-TERM ADMINISTRATION INHIBITS ATHEROGENESIS IN THE CORONARY-ARTERIES OF RATS WITH EXPERIMENTAL ATHEROSCLEROSIS [J].
TSUTSUMI, K ;
INOUE, Y ;
SHIMA, A ;
IWASAKI, K ;
KAWAMURA, M ;
MURASE, T .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :411-417
[13]   Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555 [J].
Upton, R ;
Widdowson, PS ;
Ishii, S ;
Tanaka, H ;
Williams, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (08) :1708-1714